http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2085584-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e70c0aeade92d7571d955d3b90ea06e
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
filingDate 1991-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0d201de9f46fc45c136b45d52ff91e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4b7cd798c5fac7955952608cb3e792b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1c31e1257c186313f7f7f253b718302
publicationDate 1991-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2085584-A1
titleOfInvention Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
abstract Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole and pharmaceutically acceptable salts thereof are useful for treating chronic renal failure, mediated by angiotensin-II.
priorityDate 1990-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415828093
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581195
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID183
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565336
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45266664
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546850
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID130762
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24179

Total number of triples: 38.